To observe whether CFZ is effective in a triple-negative ruxolitinib-resistant MF patient, CD34+ cells from patient MF#9, who had shown progressive splenomegaly associated with lack of symptom control and no improvement of anaemia, were treated with CFZ at various doses ranging from 10 to 1000 nM and their viability/proliferation was measured at 48 h using MTS assay. The gene discussed is CD34; the disease is anemia (phenotype).